Arbutus Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Arbutus Biopharma Corp
ABUS Stock  USD 4.48  0.07  1.54%   
Arbutus Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Arbutus Biopharma's valuation are provided below:
Gross Profit
-37.4 M
Market Capitalization
858.8 M
Enterprise Value Revenue
49.5413
Revenue
15.4 M
Earnings Share
(0.29)
There are over one hundred nineteen available fundamental signals for Arbutus Biopharma Corp, which can be analyzed over time and compared to other ratios. All traders should validate Arbutus Biopharma's prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 637.3 M in 2025. Enterprise Value is likely to gain to about 600.5 M in 2025

Arbutus Biopharma Total Revenue

5.86 Million

Check Arbutus Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arbutus Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 130.2 K or Selling General Administrative of 12.6 M, as well as many indicators such as Price To Sales Ratio of 103, Dividend Yield of 0.0529 or PTB Ratio of 7.98. Arbutus financial statements analysis is a perfect complement when working with Arbutus Biopharma Valuation or Volatility modules.
  
Build AI portfolio with Arbutus Stock
Check out the analysis of Arbutus Biopharma Correlation against competitors.

Arbutus Biopharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets125.2 M131.7 M173.1 M
Pretty Stable
Other Current Liabilities5.7 M5.2 M6.7 M
Pretty Stable
Total Current Liabilities10.1 M15.6 M12.4 M
Slightly volatile
Total Stockholder Equity94 M97.4 M132.5 M
Very volatile
Property Plant And Equipment Net4.8 M4.4 M5.8 M
Slightly volatile
Cash39.9 M36.3 M50.4 M
Very volatile
Non Current Assets Total4.2 M4.4 M64 M
Pretty Stable
Cash And Short Term Investments75.9 M122.6 M102.9 M
Slightly volatile
Net Receivables1.4 M2.4 M1.3 M
Pretty Stable
Common Stock Shares Outstanding194.9 M185.6 M75.7 M
Slightly volatile
Liabilities And Stockholders Equity125.2 M131.7 M173.1 M
Pretty Stable
Non Current Liabilities Total24.8 M18.7 M29.4 M
Very volatile
Other Current Assets2 M2.3 M2.8 M
Slightly volatile
Total Liabilities31.2 M34.3 M40.6 M
Pretty Stable
Property Plant And Equipment Gross18.2 M17.4 M8.2 M
Slightly volatile
Total Current Assets78.9 M127.3 M106.4 M
Slightly volatile
Common Stock1.4 B1.4 B1.4 B
Pretty Stable
Short and Long Term Debt Total1.2 M1.3 M9.7 M
Slightly volatile
Other Liabilities18.6 M27.5 M27 M
Very volatile
Accounts Payable2.4 M2.3 M2.4 M
Slightly volatile
Property Plant Equipment4.5 M5.8 M5.2 M
Slightly volatile
Current Deferred Revenue4.7 M7.6 M5.2 M
Slightly volatile
Capital Surpluse53.5 M83.3 M47 M
Slightly volatile
Non Current Liabilities Other15.4 M15.1 M12.1 M
Slightly volatile
Long Term Debt Total9.6 M10.8 M11.8 M
Slightly volatile
Net Working Capital127.3 M111.7 M116 M
Pretty Stable
Capital Stock1.3 B1.4 B1.1 B
Slightly volatile
Capital Lease Obligations1.9 M1.3 M2.9 M
Slightly volatile

Arbutus Biopharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.4 M1.4 M1.3 M
Slightly volatile
Selling General Administrative12.6 M22.1 M17 M
Slightly volatile
Total Revenue5.9 M6.2 M12.4 M
Very volatile
Other Operating Expenses50.4 M82.5 M64 M
Slightly volatile
Research Development51.3 M54 M48.4 M
Slightly volatile
Cost Of Revenue1.3 M1.4 M32.9 M
Very volatile
Interest Income3.9 M6.6 M11.3 M
Slightly volatile
Preferred Stock And Other Adjustments10.2 M14 M6.3 M
Slightly volatile
Reconciled Depreciation1.4 M1.4 M1.9 M
Slightly volatile
Selling And Marketing Expenses1.1 M1.3 M1.4 M
Slightly volatile

Arbutus Biopharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow38.8 M26.3 M48.8 M
Pretty Stable
Other Cashflows From Financing Activities9.5 M7.9 M14.3 M
Pretty Stable
Depreciation1.4 M1.4 M1.3 M
Slightly volatile
Capital Expenditures172.9 K182 K1.5 M
Pretty Stable
Total Cash From Financing Activities35.2 M52 M48.4 M
Slightly volatile
End Period Cash Flow39.9 M36.3 M50.4 M
Very volatile
Stock Based Compensation8.7 M9 M8.9 M
Pretty Stable
Issuance Of Capital Stock45.3 M44.1 M60.7 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10398.353833.7238
Slightly volatile
Dividend Yield0.05290.03380.0449
Slightly volatile
PTB Ratio7.986.23362.6989
Slightly volatile
Days Sales Outstanding73.4714262.0005
Pretty Stable
Book Value Per Share0.50.52462.9798
Slightly volatile
Average Payables1.2 M1.1 M1.2 M
Pretty Stable
Stock Based Compensation To Revenue1.631.45622.2664
Very volatile
Capex To Depreciation0.130.13191.273
Slightly volatile
PB Ratio7.986.23362.6989
Slightly volatile
EV To Sales97.3192.675429.1493
Slightly volatile
Payables Turnover0.570.595915.4735
Slightly volatile
Sales General And Administrative To Revenue2.353.58263.1765
Very volatile
Research And Ddevelopement To Revenue8.328.75667.3685
Very volatile
Capex To Revenue0.0280.02950.4192
Slightly volatile
Cash Per Share0.630.66072.2259
Slightly volatile
Days Payables Outstanding643613190
Slightly volatile
Income Quality0.830.92750.7485
Pretty Stable
Intangibles To Total Assets0.240.260.4393
Slightly volatile
Current Ratio6.828.15199.1935
Pretty Stable
Tangible Book Value Per Share0.50.52461.7872
Slightly volatile
Receivables Turnover2.432.561611.2283
Pretty Stable
Shareholders Equity Per Share0.50.52462.9798
Slightly volatile
Debt To Equity0.01260.01320.0428
Slightly volatile
Capex Per Share9.0E-40.0010.119
Slightly volatile
Graham Net Net0.460.48541.4248
Slightly volatile
Average Receivables1 M1.7 M1.8 M
Very volatile
Revenue Per Share0.03160.03320.3974
Slightly volatile
Interest Debt Per Share0.00730.00770.0946
Slightly volatile
Debt To Assets0.0170.00980.032
Slightly volatile
Graham Number5.6610.8910.9915
Very volatile
Price Book Value Ratio7.986.23362.6989
Slightly volatile
Days Of Payables Outstanding643613190
Slightly volatile
Company Equity Multiplier2.681.35271.4683
Pretty Stable
Long Term Debt To Capitalization0.05820.05540.0558
Slightly volatile
Total Debt To Capitalization0.01240.01310.0406
Slightly volatile
Debt Equity Ratio0.01260.01320.0428
Slightly volatile
Quick Ratio6.838.15199.245
Pretty Stable
Net Income Per E B T0.760.960.9359
Very volatile
Cash Ratio2.212.32624.326
Pretty Stable
Days Of Sales Outstanding73.4714262.0005
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.221.00281.0731
Slightly volatile
Price To Book Ratio7.986.23362.6989
Slightly volatile
Fixed Asset Turnover1.351.41633.8534
Slightly volatile
Debt Ratio0.0170.00980.032
Slightly volatile
Price Sales Ratio10398.353833.7238
Slightly volatile
Asset Turnover0.04450.04690.1605
Slightly volatile
Price Fair Value7.986.23362.6989
Slightly volatile

Arbutus Biopharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap637.3 M606.9 M273.6 M
Slightly volatile
Enterprise Value600.5 M571.9 M221.2 M
Slightly volatile

Arbutus Fundamental Market Drivers

Cash And Short Term Investments122.6 M

Arbutus Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Arbutus Biopharma Financial Statements

Arbutus Biopharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Arbutus Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Arbutus Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Arbutus Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue7.6 M4.7 M
Total Revenue6.2 M5.9 M
Cost Of Revenue1.4 M1.3 M
Stock Based Compensation To Revenue 1.46  1.63 
Sales General And Administrative To Revenue 3.58  2.35 
Research And Ddevelopement To Revenue 8.76  8.32 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.03  0.03 
Ebit Per Revenue(12.37)(12.99)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Arbutus Stock Analysis

When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY